This is the largest series of patients with mesial temporal lobe epilepsy who have undergone subtemporal selective amygdalohippocampectomy (MTLE) This is a minimally invasive procedure for the treatment of MTLE that looks to be both safe and successful. All patients who underwent a sSAH by the senior author (K.A.S.) between April 2004 and April 2017 had their medical records reviewed retrospectively. The study comprised patients with medication resistant epilepsy who had had a comprehensive epilepsy neurology examination and were advised for amygdala and hippocampal resection. A neurological examination was performed on all of the patients.The sSAH method is a minimally invasive treatment for MTLE that appears to be both safe and successful.
The safety of the sSAH method for the surgical treatment of MTLE is demonstrated by this minimally invasive procedure. Patients were divided into two categories: “skip” candidates and “nonskip” candidates. The seizure outcome evaluations at one year, as well as any subsequent annual assessments, were reviewed retrospectively. All patients were also examined for postoperative problems.Seizure results, complications, preoperative factors, and patient demographic variables were all reviewed retrospectively for included patients’ data. The study was linked to positive seizure outcomes and a low rate of complications. For all analyses, a significance level of 0.05 was used.A keyhole craniotomy can be used to finish the excision with minimum disturbance to the anterolateral temporal lobe.
Refence Link – https://thejns.org/view/journals/j-neurosurg/134/6/article-p1685.xml?body=fullText
